IBIO

iBio is a preclinical-stage biotech with no approved products, no human clinical data, and effectively no commercial revenue ($400K FY2025, immaterial milestone/grant income on which the 85x P/S and 541.8% 'gross margin' are nonsensical artifacts). Its entire value rests on an early obesity/cardiometabolic antibody pipeline (IBIO-610 anti-Activin E, a myostatin×Activin A bispecific) whose evidence to date is DIO mouse models with non-responders explicitly excluded. Management itself only 'anticipates the commencement of our first human clinical trials in late fiscal 2026 or early fiscal 2027' — meaning every program is still pre-IND with no proof of human translation.

The balance sheet makes this urgent, not patient. Operating cash flow was -$15.3M in FY2025 against just $8.58M of cash (down 39.6% YoY), implying well under a year of runway before the next raise. Current liabilities jumped 59% to $6.11M while current assets fell 38% to $9.72M, and R&D spend rose 60% to $8.31M — burn is accelerating into a depleting treasury. The only way this company funds its first clinical trial is by issuing more stock, and it already has: shares outstanding rose 127.5% YoY to 19.7M, and accumulated deficit stands at -$332M. Existing holders have been, and will continue to be, heavily diluted.